Patents by Inventor Philip Cohen

Philip Cohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10706679
    Abstract: An electronic wagering system may include a wager selection station, a server, and a software application executed by a mobile communication device. At least one processor of the wager selection station may accept user input specifying parameters of an event on which to place a wager, generate a unique reference from which the specified event parameters are derivable, encode the unique reference in a machine-readable optical code, and display the generated optical code. The software application may operate the user's mobile communication device to scan the displayed optical code, retrieve the unique reference by decoding the scanned optical code, transmit the unique reference to the server for deriving the specified event parameters from the unique reference at the server, receive user input to place a wager on the event with the specified parameters, and transmit a request to the server to place the wager on behalf of the user.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: July 7, 2020
    Assignee: IGT
    Inventors: Charles Philip Cohen, Christian Mario Bugno
  • Patent number: 10460036
    Abstract: The disclosure relates to transferred learning from a first language (e.g., a source language for which a semantic parser has been defined) to a second language (e.g., a target language for which a semantic parser has not been defined). A system may use knowledge from a trained model in one language to model another language. For example, the system may transfer knowledge of a semantic parser from a first (e.g., source) language to a second (e.g., target) language. Such transfer of knowledge may occur and be useful when the first language has sufficient training data but the second language has insufficient training data. The foregoing transfer of knowledge may extend the semantic parser for multiple languages (e.g., the first language and the second language).
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 29, 2019
    Assignee: Voicebox Technologies Corporation
    Inventors: Long Duong, Hadi Afshar, Dominique Estival, Glen Pink, Philip Cohen, Mark Edward Johnson
  • Patent number: 10233157
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 19, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Publication number: 20180307679
    Abstract: The disclosure relates to transferred learning from a first language (e.g., a source language for which a semantic parser has been defined) to a second language (e.g., a target language for which a semantic parser has not been defined). A system may use knowledge from a trained model in one language to model another language. For example, the system may transfer knowledge of a semantic parser from a first (e.g., source) language to a second (e.g., target) language. Such transfer of knowledge may occur and be useful when the first language has sufficient training data but the second language has insufficient training data. The foregoing transfer of knowledge may extend the semantic parser for multiple languages (e.g., the first language and the second language).
    Type: Application
    Filed: April 23, 2018
    Publication date: October 25, 2018
    Inventors: Long DUONG, Hadi AFSHAR, Dominique ESTIVAL, Glen PINK, Philip COHEN, Mark Edward JOHNSON
  • Publication number: 20180215719
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: May 26, 2017
    Publication date: August 2, 2018
    Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Publication number: 20170345256
    Abstract: An electronic wagering system may include a wager selection station, a server, and a software application executed by a mobile communication device. At least one processor of the wager selection station may accept user input specifying parameters of an event on which to place a wager, generate a unique reference from which the specified event parameters are derivable, encode the unique reference in a machine-readable optical code, and display the generated optical code. The software application may operate the user's mobile communication device to scan the displayed optical code, retrieve the unique reference by decoding the scanned optical code, transmit the unique reference to the server for deriving the specified event parameters from the unique reference at the server, receive user input to place a wager on the event with the specified parameters, and transmit a request to the server to place the wager on behalf of the user.
    Type: Application
    Filed: May 27, 2016
    Publication date: November 30, 2017
    Inventors: Charles Philip Cohen, Christian Mario Bugno
  • Publication number: 20170342036
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicants: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael S. Gray
  • Patent number: 9670165
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: June 6, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., University Court of the University of Dundee
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael Gray
  • Publication number: 20170044136
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
    Type: Application
    Filed: April 6, 2016
    Publication date: February 16, 2017
    Inventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
  • Publication number: 20150376178
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
    Type: Application
    Filed: June 5, 2014
    Publication date: December 31, 2015
    Inventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
  • Patent number: 8999955
    Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4?H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5??H or a C1-C12 alkyl, —R6?H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8?H, C1-C12 alkyl; —R9 and R10?H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: April 7, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Philippe Olivier Belmont, Laurent Meijer, Philip Cohen, Amaury Patin, Johann Bosson, Peter Gregory Goekjian
  • Publication number: 20150045370
    Abstract: The present invention relates to the discovery that salt inducible kinases (SIKs) suppress the formation of anti-inflammatory molecules such as IL-10, which are important for the resolution of inflammation and identifies SIK inhibitors that may be used to treat disorders associated with undesirable inflammation, such as inflammatory bowel disease and/or autoimmune disorders.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 12, 2015
    Inventors: Philip Cohen, Kristopher Clark, Hwan Geun Choi, Nathanael Gray
  • Patent number: 8748459
    Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTlF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: June 10, 2014
    Assignee: Eli Lilly and Company
    Inventors: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, Deyi Zhang
  • Patent number: 8481586
    Abstract: The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: July 9, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite Blaise Pascal-Clermont-Ferrand II
    Inventors: Fabrice Anizon, Pascale Moreau, Michelle Prudhomme, Philip Cohen, Bettina Aboab, Rufine Akue-Gedu, Emilie Rossignol
  • Patent number: 8202873
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently —C(H)? or —N?, provided that at least one of A and B is —N?, n is 1-3, m is 0-3, and R1-4 are as defined herein.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: June 19, 2012
    Assignee: Eli Lilly and Company
    Inventors: Valentina O. Badescu, Anne Marie Camp, Barry Peter Clark, Michael Philip Cohen, Sandra Ann Filla, Peter Thaddeus Gallagher, Sarah Lynne Hellman, Michael Philip Mazanetz, Marta Maria Pineiro-Nunez, John Mehnert Schaus, Patrick Gianpietro Spinazze, Maria Ann Whatton
  • Publication number: 20120149975
    Abstract: An adjustable gastric band (AGB) positionable around a human stomach to limit the flow of food therethrough is provided with an improved structure for receiving and retaining suture from the stomach to the gastric restrictive device and thereby enabling a safer gastro-gastric plication while simultaneously preventing movement of the gastric fundus relative to the gastric restrictive device while additionally reducing the risk of tissue in-growth around and through the fenestrations, apertures or interstices of prior adjustable gastric band (AGB) structures for receiving and retaining sutures, which will render this embodiment safer in regard to the need for any potential revision procedures which may require relocating, removing or replacing the adjustable gastric bands in the future as well as enabling a safer gastro-gastricbuttress plication which will reduce the incidence of both “slippage” and “erosion.
    Type: Application
    Filed: December 8, 2011
    Publication date: June 14, 2012
    Inventor: Philip Cohen
  • Publication number: 20120028961
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is —S—R14; and other substituents are as defined in the specification.
    Type: Application
    Filed: July 28, 2011
    Publication date: February 2, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: JOHN GORDON ALLEN, Karin Briner, Michael Philip Cohen, Christopher Stanley Galka, Sarah Lynne Hellman, Maria Angeles Martinez-Grau, Matthew Robert Reinhard, Michael John Rodriguez, Roger Ryan Rothhaar, Michael Wade Tidwell, Frantz Victor, Andrew Caerwyn Williams, Deyi Zhang, Steven Armen Boyd, Richard Gerard Conway, Arundhati S. Deo, Wai-Man Lee, Christopher Stephen Siedem, Ajay Singh, Michael Philip MAZANETZ
  • Publication number: 20110275102
    Abstract: The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.
    Type: Application
    Filed: February 4, 2011
    Publication date: November 10, 2011
    Applicant: NOVARTIS AG
    Inventors: Dario Alessi, Mirjana Andjelkovic, Philip Cohen, Peter David Cron, Darren Cross, Brian A. Hemmings
  • Patent number: 8048884
    Abstract: The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is —C(H)? or —N?; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyridyl, or thienyl; R2 is hydrogen or methyl; and R3 and R4 are as defined herein.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: November 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Michael Philip Cohen, Sarah Lynne Hellman, Sean Patrick Hollinshead, Sandra Ann Filla, Michael Wade Tidwell
  • Publication number: 20110263669
    Abstract: The invention relates to pyrrolo[2,3-a]carbazole derivatives, to a method for preparing the same, and to the use thereof as PIM kinase inhibitors. The invention can particularly be used in the pharmaceutical field.
    Type: Application
    Filed: June 25, 2009
    Publication date: October 27, 2011
    Inventors: Fabrice Anizon, Pascale Moreau, Michelle Prudhomme, Philip Cohen, Bettina Aboab, Rufine Akue-Gedu, Emilie Rossignol